Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9934 |
High Similarity |
NPD247 |
Clinical (unspecified phase) |
0.947 |
High Similarity |
NPD218 |
Approved |
0.947 |
High Similarity |
NPD216 |
Approved |
0.947 |
High Similarity |
NPD217 |
Approved |
0.947 |
High Similarity |
NPD220 |
Clinical (unspecified phase) |
0.947 |
High Similarity |
NPD219 |
Phase 3 |
0.9272 |
High Similarity |
NPD213 |
Clinical (unspecified phase) |
0.9272 |
High Similarity |
NPD214 |
Approved |
0.902 |
High Similarity |
NPD338 |
Approved |
0.8961 |
High Similarity |
NPD339 |
Approved |
0.8889 |
High Similarity |
NPD283 |
Approved |
0.8774 |
High Similarity |
NPD242 |
Approved |
0.8662 |
High Similarity |
NPD169 |
Phase 2 |
0.8497 |
Intermediate Similarity |
NPD250 |
Approved |
0.8497 |
Intermediate Similarity |
NPD249 |
Approved |
0.8439 |
Intermediate Similarity |
NPD4054 |
Clinical (unspecified phase) |
0.8387 |
Intermediate Similarity |
NPD186 |
Discovery |
0.8387 |
Intermediate Similarity |
NPD195 |
Approved |
0.8187 |
Intermediate Similarity |
NPD4716 |
Approved |
0.814 |
Intermediate Similarity |
NPD4744 |
Clinical (unspecified phase) |
0.8129 |
Intermediate Similarity |
NPD185 |
Approved |
0.8118 |
Intermediate Similarity |
NPD4171 |
Clinical (unspecified phase) |
0.8075 |
Intermediate Similarity |
NPD1750 |
Clinical (unspecified phase) |
0.8075 |
Intermediate Similarity |
NPD3107 |
Discontinued |
0.8075 |
Intermediate Similarity |
NPD1369 |
Phase 2 |
0.807 |
Intermediate Similarity |
NPD1412 |
Clinical (unspecified phase) |
0.8061 |
Intermediate Similarity |
NPD3083 |
Approved |
0.8037 |
Intermediate Similarity |
NPD2624 |
Phase 2 |
0.8025 |
Intermediate Similarity |
NPD166 |
Approved |
0.8024 |
Intermediate Similarity |
NPD7988 |
Suspended |
0.8 |
Intermediate Similarity |
NPD193 |
Suspended |
0.7927 |
Intermediate Similarity |
NPD2646 |
Discontinued |
0.7927 |
Intermediate Similarity |
NPD1732 |
Phase 3 |
0.7853 |
Intermediate Similarity |
NPD6417 |
Clinical (unspecified phase) |
0.7716 |
Intermediate Similarity |
NPD548 |
Clinical (unspecified phase) |
0.7667 |
Intermediate Similarity |
NPD2631 |
Clinical (unspecified phase) |
0.7667 |
Intermediate Similarity |
NPD2632 |
Approved |
0.7667 |
Intermediate Similarity |
NPD2630 |
Approved |
0.7647 |
Intermediate Similarity |
NPD9632 |
Phase 3 |
0.756 |
Intermediate Similarity |
NPD4074 |
Clinical (unspecified phase) |
0.7558 |
Intermediate Similarity |
NPD2647 |
Phase 3 |
0.7516 |
Intermediate Similarity |
NPD252 |
Clinical (unspecified phase) |
0.7515 |
Intermediate Similarity |
NPD3086 |
Phase 3 |
0.7455 |
Intermediate Similarity |
NPD3085 |
Phase 1 |
0.7443 |
Intermediate Similarity |
NPD5666 |
Phase 2 |
0.7434 |
Intermediate Similarity |
NPD9084 |
Phase 2 |
0.7423 |
Intermediate Similarity |
NPD1730 |
Discontinued |
0.7348 |
Intermediate Similarity |
NPD1692 |
Approved |
0.7308 |
Intermediate Similarity |
NPD248 |
Discontinued |
0.7294 |
Intermediate Similarity |
NPD546 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD7158 |
Phase 1 |
0.7244 |
Intermediate Similarity |
NPD9633 |
Phase 3 |
0.7233 |
Intermediate Similarity |
NPD194 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD549 |
Approved |
0.72 |
Intermediate Similarity |
NPD1776 |
Approved |
0.72 |
Intermediate Similarity |
NPD1777 |
Approved |
0.7168 |
Intermediate Similarity |
NPD516 |
Clinical (unspecified phase) |
0.7161 |
Intermediate Similarity |
NPD9408 |
Phase 3 |
0.716 |
Intermediate Similarity |
NPD9605 |
Phase 3 |
0.7081 |
Intermediate Similarity |
NPD5683 |
Clinical (unspecified phase) |
0.7081 |
Intermediate Similarity |
NPD5682 |
Phase 3 |
0.7081 |
Intermediate Similarity |
NPD5684 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD870 |
Clinical (unspecified phase) |
0.703 |
Intermediate Similarity |
NPD582 |
Approved |
0.6981 |
Remote Similarity |
NPD8829 |
Clinical (unspecified phase) |
0.6957 |
Remote Similarity |
NPD9083 |
Clinical (unspecified phase) |
0.6909 |
Remote Similarity |
NPD3695 |
Approved |
0.6909 |
Remote Similarity |
NPD3696 |
Approved |
0.6901 |
Remote Similarity |
NPD353 |
Discontinued |
0.6772 |
Remote Similarity |
NPD7138 |
Phase 2 |
0.6763 |
Remote Similarity |
NPD536 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD171 |
Discontinued |
0.6588 |
Remote Similarity |
NPD4240 |
Approved |
0.6561 |
Remote Similarity |
NPD9607 |
Approved |
0.6552 |
Remote Similarity |
NPD3708 |
Phase 2 |
0.6545 |
Remote Similarity |
NPD1063 |
Phase 2 |
0.6541 |
Remote Similarity |
NPD8830 |
Phase 3 |
0.6497 |
Remote Similarity |
NPD9606 |
Approved |
0.649 |
Remote Similarity |
NPD5080 |
Phase 2 |
0.6485 |
Remote Similarity |
NPD2877 |
Clinical (unspecified phase) |
0.6485 |
Remote Similarity |
NPD2876 |
Phase 3 |
0.6446 |
Remote Similarity |
NPD209 |
Clinical (unspecified phase) |
0.6442 |
Remote Similarity |
NPD5079 |
Phase 2 |
0.6436 |
Remote Similarity |
NPD2965 |
Clinical (unspecified phase) |
0.6422 |
Remote Similarity |
NPD2824 |
Phase 2 |
0.6415 |
Remote Similarity |
NPD9409 |
Discontinued |
0.6386 |
Remote Similarity |
NPD545 |
Clinical (unspecified phase) |
0.6384 |
Remote Similarity |
NPD231 |
Clinical (unspecified phase) |
0.6347 |
Remote Similarity |
NPD6840 |
Approved |
0.6306 |
Remote Similarity |
NPD9374 |
Approved |
0.6293 |
Remote Similarity |
NPD796 |
Phase 2 |
0.6287 |
Remote Similarity |
NPD547 |
Clinical (unspecified phase) |
0.625 |
Remote Similarity |
NPD307 |
Approved |
0.623 |
Remote Similarity |
NPD1046 |
Clinical (unspecified phase) |
0.622 |
Remote Similarity |
NPD2903 |
Clinical (unspecified phase) |
0.622 |
Remote Similarity |
NPD2902 |
Phase 2 |
0.6197 |
Remote Similarity |
NPD537 |
Phase 2 |
0.6197 |
Remote Similarity |
NPD534 |
Phase 2 |
0.6178 |
Remote Similarity |
NPD9373 |
Approved |
0.6158 |
Remote Similarity |
NPD775 |
Approved |
0.6142 |
Remote Similarity |
NPD2152 |
Clinical (unspecified phase) |
0.6124 |
Remote Similarity |
NPD4495 |
Phase 1 |
0.6092 |
Remote Similarity |
NPD1430 |
Approved |
0.6092 |
Remote Similarity |
NPD1431 |
Approved |
0.6084 |
Remote Similarity |
NPD9366 |
Approved |
0.6036 |
Remote Similarity |
NPD282 |
Approved |
0.6023 |
Remote Similarity |
NPD1119 |
Phase 2 |
0.5989 |
Remote Similarity |
NPD527 |
Clinical (unspecified phase) |
0.5935 |
Remote Similarity |
NPD9626 |
Clinical (unspecified phase) |
0.592 |
Remote Similarity |
NPD1808 |
Phase 1 |
0.5917 |
Remote Similarity |
NPD6381 |
Phase 2 |
0.5909 |
Remote Similarity |
NPD2253 |
Discontinued |
0.5855 |
Remote Similarity |
NPD4089 |
Clinical (unspecified phase) |
0.5837 |
Remote Similarity |
NPD4713 |
Clinical (unspecified phase) |
0.5837 |
Remote Similarity |
NPD34 |
Approved |
0.5837 |
Remote Similarity |
NPD4714 |
Approved |
0.5837 |
Remote Similarity |
NPD4715 |
Clinical (unspecified phase) |
0.5818 |
Remote Similarity |
NPD6036 |
Suspended |
0.5813 |
Remote Similarity |
NPD9375 |
Discontinued |
0.5805 |
Remote Similarity |
NPD1120 |
Approved |
0.5805 |
Remote Similarity |
NPD1121 |
Approved |
0.5765 |
Remote Similarity |
NPD1127 |
Approved |
0.5765 |
Remote Similarity |
NPD1128 |
Approved |
0.5743 |
Remote Similarity |
NPD207 |
Discontinued |
0.5742 |
Remote Similarity |
NPD4459 |
Clinical (unspecified phase) |
0.5742 |
Remote Similarity |
NPD4458 |
Phase 2 |
0.574 |
Remote Similarity |
NPD281 |
Approved |
0.5706 |
Remote Similarity |
NPD515 |
Phase 1 |
0.569 |
Remote Similarity |
NPD1058 |
Discontinued |
0.5682 |
Remote Similarity |
NPD9550 |
Approved |
0.5682 |
Remote Similarity |
NPD6112 |
Approved |
0.5682 |
Remote Similarity |
NPD9551 |
Approved |
0.5659 |
Remote Similarity |
NPD7531 |
Clinical (unspecified phase) |
0.5625 |
Remote Similarity |
NPD535 |
Approved |
0.5622 |
Remote Similarity |
NPD7842 |
Phase 2 |
0.5619 |
Remote Similarity |
NPD9582 |
Phase 3 |
0.561
|
Remote Similarity |
NPD9584 |
Phase 2 |